中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2013年
14期
23-24
,共2页
郑玮%樊惠谊%梁小曼%徐燕
鄭瑋%樊惠誼%樑小曼%徐燕
정위%번혜의%량소만%서연
血管抑素%微血管密度%子宫内膜癌
血管抑素%微血管密度%子宮內膜癌
혈관억소%미혈관밀도%자궁내막암
Angiostatin%Microvessel demist%Endometrial cancer
目的研究血管生长抑制素(AS)和微血管密度(MVD)在子宫内膜癌中的表达及临床应用价值。方法增生期子宫内膜组,子宫内膜增殖症组,子宫内膜癌组各30例,采用免疫组织化学法检测其子宫内膜组织中AS及MVD的表达结果。结果(1)子宫内膜癌组与增生期子宫内膜组、子宫内膜增殖症组间MVD、AS间的差异有统计学意义(P<0.05);(2)血管抑素与MVD的表达有相关性(rs=0.706,P<0.05)。结论 AS和MVD在子宫内膜癌的发生发展中起到重要作用,可以考虑将它们看做子宫内膜癌的潜在侵袭性方面的肿瘤标志物,作为抗肿瘤治疗的新靶标。
目的研究血管生長抑製素(AS)和微血管密度(MVD)在子宮內膜癌中的錶達及臨床應用價值。方法增生期子宮內膜組,子宮內膜增殖癥組,子宮內膜癌組各30例,採用免疫組織化學法檢測其子宮內膜組織中AS及MVD的錶達結果。結果(1)子宮內膜癌組與增生期子宮內膜組、子宮內膜增殖癥組間MVD、AS間的差異有統計學意義(P<0.05);(2)血管抑素與MVD的錶達有相關性(rs=0.706,P<0.05)。結論 AS和MVD在子宮內膜癌的髮生髮展中起到重要作用,可以攷慮將它們看做子宮內膜癌的潛在侵襲性方麵的腫瘤標誌物,作為抗腫瘤治療的新靶標。
목적연구혈관생장억제소(AS)화미혈관밀도(MVD)재자궁내막암중적표체급림상응용개치。방법증생기자궁내막조,자궁내막증식증조,자궁내막암조각30례,채용면역조직화학법검측기자궁내막조직중AS급MVD적표체결과。결과(1)자궁내막암조여증생기자궁내막조、자궁내막증식증조간MVD、AS간적차이유통계학의의(P<0.05);(2)혈관억소여MVD적표체유상관성(rs=0.706,P<0.05)。결론 AS화MVD재자궁내막암적발생발전중기도중요작용,가이고필장타문간주자궁내막암적잠재침습성방면적종류표지물,작위항종류치료적신파표。
Objective To investigate the expression and significance of angiostatin and microvessel demist in endometrial and the clinical investigation. Methods The immunohistochemical method was used to detect the expression of AS and microvessel demist in 30 adenocarcinoma endometrial,30 endometrial hyperplasia and 30 endometrial cancer. Results First,the levels of MVD showed a significant difference between adenocarcinoma endometrial,endometrial hyperplasia and endometrial cancer(P < 0.05);Second,the expression of angiostatin was associated with MVD (rs=0.706,P<0.05). Conclusion The results clue on the important role of AS and MVD on the development of endometrial earcinoma. Additional we can treat them as endometrial eareinoma potential invasive tumor markers and as the anti-tumor therapy of important novel targets.